Results 211 to 220 of about 16,818,363 (252)

The quantification and epistemology of medicines use and polypharmacy tested in an observational study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Definitions of ‘medicines use’ and ‘polypharmacy’ may refer to all medicines, regular long‐term medicines or another subset. Valid definitions of medicines use should incorporate type of use (long term, short course and as needed [PRN]), changes in use (start, stop and dose change) and a description of temporal examination (cross‐sectional or ...
Lorna Pairman, Paul Chin, Matthew Doogue
wiley   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano   +6 more
wiley   +1 more source

Impact of the pancreatic enzyme replacement therapy (PERT) shortage on prescribing in England: Analysis of national data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Pancreatic enzyme replacement therapy (PERT) is essential for the management of pancreatic exocrine insufficiency. Since June 2023, the United Kingdom has been affected by a global shortage of PERT. We investigated the impact of this shortage on national prescribing trends for Creon, Nutrizym, Pancrex and Pangrol.
Teena S. Varghese   +6 more
wiley   +1 more source

Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID‐19 and adverse outcomes on prescribing patterns in England remains uncertain.
Alvina Chaudhry   +3 more
wiley   +1 more source

Analysis of clinical investigation (device) initial submissions received by the Medicines and Healthcare products Regulatory Agency between January 2022 and December 2025

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse clinical investigation‐device initial submissions received by the MHRA between January 2022 and December 2025. Methods Data on submissions were extracted from the clinical investigations unit data bank; software as medical devices were not included. The predefined primary end‐point was submission type.
Andrea Manfrin   +7 more
wiley   +1 more source

Defining a comprehensive set of value assessment criteria for funders of drug repurposing initiatives

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aims to develop a structured list of value assessment criteria for drug repurposing (DR) projects designed to support consistent, evidence‐informed decision‐making by funders. The assessment criteria were developed within the REMEDi4ALL project, a multi‐stakeholder Horizon Europe funded initiative to advance DR and were validated ...
Dalma Hosszú   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy